Who is sponsoring NCT06793332?

NCT06793332 is sponsored by Fudan University.

What drugs are being tested in NCT06793332?

Interventions in NCT06793332: Ivonescimab Combined With TROP2 ADC.

What condition does NCT06793332 study?

NCT06793332 studies Triple-Negative Breast Cancer (TNBC), Brain Metastases.

Is NCT06793332 still recruiting?

NCT06793332 is currently recruiting now. Last updated 27 January 2025.

Last reviewed 2025-01-27 · How we verify

NCT06793332: BALISTA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC

Recruiting now Phase 2 Last updated 27 January 2025

What this trial tests

Phase 2 trial testing Ivonescimab Combined With TROP2 ADC in Triple-Negative Breast Cancer (TNBC) in 39 participants. Currently enrolling.

Timeline

17 December 2024

Primary endpoint
31 January 2026

31 January 2027

Quick facts

Lead sponsor	Fudan University
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	39
Start date	17 December 2024
Primary completion	31 January 2026
Estimated completion	31 January 2027
Sites	1 location across China

Drugs / interventions tested

Ivonescimab Combined With TROP2 ADC — full drug profile →

Conditions studied

Triple-Negative Breast Cancer (TNBC) — all drugs for Triple-Negative Breast Cancer (TNBC) →
Brain Metastases — all drugs for Brain Metastases →

Sponsor

Fudan University

Who can join

Adults 18 to 70, any sex, with Triple-Negative Breast Cancer (TNBC) or Brain Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a single-center, prospective, single-arm clinical trial, which intends to enroll patients with triple-negative breast cancer with brain metastases to receive ivonescimab combined with TROP2 ADC (such as sacituzumab govitecan) treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or the investigator deems it necessary to discontinue the medication, and to collect data on the drug's efficacy and safety.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Characterization of TROP-2 bispecific T cell engagers for immunotherapy of triple negative breast and bladder cancer.
Ávila-Nieto C, Jung G, Salih HR, Hagelstein I. · · 2026 · PMID 41909703 · DOI 10.3389/fimmu.2026.1794705
Emerging Protein Targets in Triple-Negative Breast Cancer: Beyond Conventional Therapy
Previtali A, Guardamagna I, Calandra S, Shakarami M, et al · · 2026

Verify or expand the search:

Other recruiting trials for Triple-Negative Breast Cancer (TNBC)

Currently open trials in the same condition.

NCT07484776 — Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer · NA · active not recruiting
NCT07486089 — Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC) · Phase 1, PHASE2 · recruiting
NCT07208149 — A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) · Phase 1, PHASE2 · recruiting
NCT07073755 — Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, · recruiting

Other Fudan University trials

Trials by the same sponsor.

NCT06196671 — Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer · Phase 2 · not yet recruiting
NCT07423611 — ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07410559 — Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Negative Bre · Phase 2 · not yet recruiting
NCT07490119 — Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer · Phase 2 · not yet recruiting
NCT07497919 — A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06793332 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fudan University
Last refreshed: 27 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06793332.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing